Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 10 of 10 entries
Sorted by: Best Match Show Resources per page
Effect Modifiers of Low-Dose Tamoxifen in a Randomized Trial in Breast Noninvasive Disease.

Clinical cancer research : an official journal of the American Association for Cancer Research

DeCensi A, Puntoni M, Johansson H, Guerrieri-Gonzaga A, Caviglia S, Avino F, Cortesi L, Ponti A, Pacquola MG, Falcini F, Gulisano M, Digennaro M, Cariello A, Cagossi K, Pinotti G, Lazzeroni M, Serrano D, Briata IM, Buttiron Webber T, Boni L, Bonanni B.
PMID: 33608319
Clin Cancer Res. 2021 Jul 01;27(13):3576-3583. doi: 10.1158/1078-0432.CCR-20-4213. Epub 2021 Feb 19.

PURPOSE: Low-dose tamoxifen halved recurrence after surgery in a phase III trial in breast noninvasive disease without increasing adverse events. We explored the effect of low-dose tamoxifen in clinically relevant subgroups, including menopausal status, estradiol levels, smoking, body mass...

Cite
DeCensi A, Puntoni M, Johansson H, et al. Effect Modifiers of Low-Dose Tamoxifen in a Randomized Trial in Breast Noninvasive Disease. Clin Cancer Res. 2021;27(13):3576-3583doi: 10.1158/1078-0432.CCR-20-4213.
DeCensi, A., Puntoni, M., Johansson, H., Guerrieri-Gonzaga, A., Caviglia, S., Avino, F., Cortesi, L., Ponti, A., Pacquola, M. G., Falcini, F., Gulisano, M., Digennaro, M., Cariello, A., Cagossi, K., Pinotti, G., Lazzeroni, M., Serrano, D., Briata, I. M., Buttiron Webber, T., Boni, L., & Bonanni, B. (2021). Effect Modifiers of Low-Dose Tamoxifen in a Randomized Trial in Breast Noninvasive Disease. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(13), 3576-3583. https://doi.org/10.1158/1078-0432.CCR-20-4213
DeCensi, Andrea, et al. "Effect Modifiers of Low-Dose Tamoxifen in a Randomized Trial in Breast Noninvasive Disease." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,13 (2021): 3576-3583. doi: https://doi.org/10.1158/1078-0432.CCR-20-4213
DeCensi A, Puntoni M, Johansson H, Guerrieri-Gonzaga A, Caviglia S, Avino F, Cortesi L, Ponti A, Pacquola MG, Falcini F, Gulisano M, Digennaro M, Cariello A, Cagossi K, Pinotti G, Lazzeroni M, Serrano D, Briata IM, Buttiron Webber T, Boni L, Bonanni B. Effect Modifiers of Low-Dose Tamoxifen in a Randomized Trial in Breast Noninvasive Disease. Clin Cancer Res. 2021 Jul 01;27(13):3576-3583. doi: 10.1158/1078-0432.CCR-20-4213. Epub 2021 Feb 19. PMID: 33608319.
Copy Download .nbib Format: NLM
Response to Braillon.

JNCI cancer spectrum

Bonanni B, Serrano D, Maisonneuve P, Lazzeroni M, Brown PH, Guerrieri-Gonzaga A, Szabo E.
PMID: 33556158
JNCI Cancer Spectr. 2021 Jan 23;5(1):pkab005. doi: 10.1093/jncics/pkab005. eCollection 2021 Feb.

No abstract available.

Cite
Bonanni B, Serrano D, Maisonneuve P, et al. Response to Braillon. JNCI Cancer Spectr. 2021;5(1):pkab005doi: 10.1093/jncics/pkab005.
Bonanni, B., Serrano, D., Maisonneuve, P., Lazzeroni, M., Brown, P. H., Guerrieri-Gonzaga, A., & Szabo, E. (2021). Response to Braillon. JNCI cancer spectrum, 5(1), pkab005. https://doi.org/10.1093/jncics/pkab005
Bonanni, Bernardo, et al. "Response to Braillon." JNCI cancer spectrum vol. 5,1 (2021): pkab005. doi: https://doi.org/10.1093/jncics/pkab005
Bonanni B, Serrano D, Maisonneuve P, Lazzeroni M, Brown PH, Guerrieri-Gonzaga A, Szabo E. Response to Braillon. JNCI Cancer Spectr. 2021 Jan 23;5(1):pkab005. doi: 10.1093/jncics/pkab005. eCollection 2021 Feb. PMID: 33556158; PMCID: PMC7853174.
Copy Download .nbib Format: NLM
A Novel Automated Immunoassay Platform to Evaluate the Association of Adiponectin and Leptin Levels with Breast Cancer Risk.

Cancers

Macis D, Aristarco V, Johansson H, Guerrieri-Gonzaga A, Raimondi S, Lazzeroni M, Sestak I, Cuzick J, DeCensi A, Bonanni B, Gandini S.
PMID: 34209441
Cancers (Basel). 2021 Jun 30;13(13). doi: 10.3390/cancers13133303.

Adiponectin and leptin are adipokines secreted by the adipose tissue that are associated with several chronic diseases including cancer. We aimed to compare the immunoassay platform ELLA with an enzyme-linked immunosorbent assay (ELISA) kit and to assess whether the...

Cite
Macis D, Aristarco V, Johansson H, et al. A Novel Automated Immunoassay Platform to Evaluate the Association of Adiponectin and Leptin Levels with Breast Cancer Risk. Cancers (Basel). 2021;13(13)doi: 10.3390/cancers13133303.
Macis, D., Aristarco, V., Johansson, H., Guerrieri-Gonzaga, A., Raimondi, S., Lazzeroni, M., Sestak, I., Cuzick, J., DeCensi, A., Bonanni, B., & Gandini, S. (2021). A Novel Automated Immunoassay Platform to Evaluate the Association of Adiponectin and Leptin Levels with Breast Cancer Risk. Cancers, 13(13), . https://doi.org/10.3390/cancers13133303
Macis, Debora, et al. "A Novel Automated Immunoassay Platform to Evaluate the Association of Adiponectin and Leptin Levels with Breast Cancer Risk." Cancers vol. 13,13 (2021). doi: https://doi.org/10.3390/cancers13133303
Macis D, Aristarco V, Johansson H, Guerrieri-Gonzaga A, Raimondi S, Lazzeroni M, Sestak I, Cuzick J, DeCensi A, Bonanni B, Gandini S. A Novel Automated Immunoassay Platform to Evaluate the Association of Adiponectin and Leptin Levels with Breast Cancer Risk. Cancers (Basel). 2021 Jun 30;13(13). doi: 10.3390/cancers13133303. PMID: 34209441; PMCID: PMC8268385.
Copy Download .nbib Format: NLM
Association of CYP2D6 genotype and tamoxifen metabolites with breast cancer recurrence in a low-dose trial.

NPJ breast cancer

DeCensi A, Johansson H, Helland T, Puntoni M, Macis D, Aristarco V, Caviglia S, Webber TB, Briata IM, D'Amico M, Serrano D, Guerrieri-Gonzaga A, Bifulco E, Hustad S, Søiland H, Boni L, Bonanni B, Mellgren G.
PMID: 33767162
NPJ Breast Cancer. 2021 Mar 25;7(1):34. doi: 10.1038/s41523-021-00236-6.

Low-dose tamoxifen halves recurrence in non-invasive breast cancer without significant adverse events. Some adjuvant trials with tamoxifen 20 mg/day had shown an association between low endoxifen levels (9-16 nM) and recurrence, but no association with CYP2D6 was shown in...

Cite
DeCensi A, Johansson H, Helland T, et al. Association of CYP2D6 genotype and tamoxifen metabolites with breast cancer recurrence in a low-dose trial. NPJ Breast Cancer. 2021;7(1):34doi: 10.1038/s41523-021-00236-6.
DeCensi, A., Johansson, H., Helland, T., Puntoni, M., Macis, D., Aristarco, V., Caviglia, S., Webber, T. B., Briata, I. M., D'Amico, M., Serrano, D., Guerrieri-Gonzaga, A., Bifulco, E., Hustad, S., Søiland, H., Boni, L., Bonanni, B., & Mellgren, G. (2021). Association of CYP2D6 genotype and tamoxifen metabolites with breast cancer recurrence in a low-dose trial. NPJ breast cancer, 7(1), 34. https://doi.org/10.1038/s41523-021-00236-6
DeCensi, Andrea, et al. "Association of CYP2D6 genotype and tamoxifen metabolites with breast cancer recurrence in a low-dose trial." NPJ breast cancer vol. 7,1 (2021): 34. doi: https://doi.org/10.1038/s41523-021-00236-6
DeCensi A, Johansson H, Helland T, Puntoni M, Macis D, Aristarco V, Caviglia S, Webber TB, Briata IM, D'Amico M, Serrano D, Guerrieri-Gonzaga A, Bifulco E, Hustad S, Søiland H, Boni L, Bonanni B, Mellgren G. Association of CYP2D6 genotype and tamoxifen metabolites with breast cancer recurrence in a low-dose trial. NPJ Breast Cancer. 2021 Mar 25;7(1):34. doi: 10.1038/s41523-021-00236-6. PMID: 33767162; PMCID: PMC7994552.
Copy Download .nbib Format: NLM
Low-Dose Aspirin in High-Risk Individuals With Screen-Detected Subsolid Lung Nodules: A Randomized Phase II Trial.

JNCI cancer spectrum

Bonanni B, Serrano D, Maisonneuve P, Veronesi G, Johansson H, Aristarco V, Varricchio C, Cazzaniga M, Lazzeroni M, Rampinelli C, Bellomi M, Vecchi M, Spaggiari L, Vornik L, Brown PH, Beavers T, Guerrieri-Gonzaga A, Szabo E.
PMID: 33409459
JNCI Cancer Spectr. 2020 Oct 20;4(6):pkaa096. doi: 10.1093/jncics/pkaa096. eCollection 2020 Dec.

Lung cancer screening by helical low-dose computed tomography detects nonsolid nodules that may be lung adenocarcinoma precursors. Aspirin's anti-inflammatory properties make it an attractive target for prevention of multiple cancers, including lung cancer. Therefore, we conducted a phase IIb...

Cite
Bonanni B, Serrano D, Maisonneuve P, et al. Low-Dose Aspirin in High-Risk Individuals With Screen-Detected Subsolid Lung Nodules: A Randomized Phase II Trial. JNCI Cancer Spectr. 2020;4(6):pkaa096doi: 10.1093/jncics/pkaa096.
Bonanni, B., Serrano, D., Maisonneuve, P., Veronesi, G., Johansson, H., Aristarco, V., Varricchio, C., Cazzaniga, M., Lazzeroni, M., Rampinelli, C., Bellomi, M., Vecchi, M., Spaggiari, L., Vornik, L., Brown, P. H., Beavers, T., Guerrieri-Gonzaga, A., & Szabo, E. (2020). Low-Dose Aspirin in High-Risk Individuals With Screen-Detected Subsolid Lung Nodules: A Randomized Phase II Trial. JNCI cancer spectrum, 4(6), pkaa096. https://doi.org/10.1093/jncics/pkaa096
Bonanni, Bernardo, et al. "Low-Dose Aspirin in High-Risk Individuals With Screen-Detected Subsolid Lung Nodules: A Randomized Phase II Trial." JNCI cancer spectrum vol. 4,6 (2020): pkaa096. doi: https://doi.org/10.1093/jncics/pkaa096
Bonanni B, Serrano D, Maisonneuve P, Veronesi G, Johansson H, Aristarco V, Varricchio C, Cazzaniga M, Lazzeroni M, Rampinelli C, Bellomi M, Vecchi M, Spaggiari L, Vornik L, Brown PH, Beavers T, Guerrieri-Gonzaga A, Szabo E. Low-Dose Aspirin in High-Risk Individuals With Screen-Detected Subsolid Lung Nodules: A Randomized Phase II Trial. JNCI Cancer Spectr. 2020 Oct 20;4(6):pkaa096. doi: 10.1093/jncics/pkaa096. eCollection 2020 Dec. PMID: 33409459; PMCID: PMC7771428.
Copy Download .nbib Format: NLM
Chemoprevention studies within lung cancer screening programmes.

Ecancermedicalscience

Veronesi G, Guerrieri-Gonzaga A, Infante M, Bonanni B.
PMID: 26635901
Ecancermedicalscience. 2015 Nov 24;9:597. doi: 10.3332/ecancer.2015.597. eCollection 2015.

While aggressive tobacco control and help to stop smoking are essential weapons in the fight against lung cancer, screening with low-dose computed tomography (LDCT) in high-risk populations and chemoprevention may also contribute to reducing lung cancer deaths. Persons undergoing...

Cite
Veronesi G, Guerrieri-Gonzaga A, Infante M, et al. Chemoprevention studies within lung cancer screening programmes. Ecancermedicalscience. 2015;9:597doi: 10.3332/ecancer.2015.597.
Veronesi, G., Guerrieri-Gonzaga, A., Infante, M., & Bonanni, B. (2015). Chemoprevention studies within lung cancer screening programmes. Ecancermedicalscience, 9597. https://doi.org/10.3332/ecancer.2015.597
Veronesi, G, et al. "Chemoprevention studies within lung cancer screening programmes." Ecancermedicalscience vol. 9 (2015): 597. doi: https://doi.org/10.3332/ecancer.2015.597
Veronesi G, Guerrieri-Gonzaga A, Infante M, Bonanni B. Chemoprevention studies within lung cancer screening programmes. Ecancermedicalscience. 2015 Nov 24;9:597. doi: 10.3332/ecancer.2015.597. eCollection 2015. PMID: 26635901; PMCID: PMC4664502.
Copy Download .nbib Format: NLM
Hormonal Therapy and Chemoprevention.

The breast journal

Bonanni B, Guerrieri-Gonzaga A, Rotmensz N, Torrisi R, Pigatto F, Cazzaniga M, Mora S, Diani S, Robertson C, Decensi A.
PMID: 11348390
Breast J. 2000 Oct;6(5):317-323. doi: 10.1046/j.1524-4741.2000.20064.x.

Hormone replacement therapy (HRT) can increase the quality as well as the length of life, but a prolonged use can also increase the risk of breast cancer. The combination of HRT and a selective estrogen receptor modulator (SERM) such...

Cite
Bonanni B, Guerrieri-Gonzaga A, Rotmensz N, et al. Hormonal Therapy and Chemoprevention. Breast J. 2000;6(5):317-323doi: 10.1046/j.1524-4741.2000.20064.x.
Bonanni, B., Guerrieri-Gonzaga, A., Rotmensz, N., Torrisi, R., Pigatto, F., Cazzaniga, M., Mora, S., Diani, S., Robertson, C., & Decensi, A. (2000). Hormonal Therapy and Chemoprevention. The breast journal, 6(5), 317-323. https://doi.org/10.1046/j.1524-4741.2000.20064.x
Bonanni, Bernardo, et al. "Hormonal Therapy and Chemoprevention." The breast journal vol. 6,5 (2000): 317-323. doi: https://doi.org/10.1046/j.1524-4741.2000.20064.x
Bonanni B, Guerrieri-Gonzaga A, Rotmensz N, Torrisi R, Pigatto F, Cazzaniga M, Mora S, Diani S, Robertson C, Decensi A. Hormonal Therapy and Chemoprevention. Breast J. 2000 Oct;6(5):317-323. doi: 10.1046/j.1524-4741.2000.20064.x. PMID: 11348390.
Copy Download .nbib Format: NLM
The effect of transdermal estradiol or oral conjugated oestrogen and fenretinide versus placebo on haemostasis and cardiovascular risk biomarkers in a randomized breast cancer chemoprevention trial.

Ecancermedicalscience

Lazzeroni M, Macis D, Decensi A, Gandini S, Sandri MT, Serrano D, Guerrieri-Gonzaga A, Johansson H, Mora S, Daldoss C, Omodei U, Bonanni B.
PMID: 22275964
Ecancermedicalscience. 2008;2:67. doi: 10.3332/ecancer.2008.67. Epub 2008 Feb 06.

BACKGROUND: We have previously reported the favourable effect of transdermal estradiol (E2), relative to oral conjugated equine oestrogen (CEE), on ultrasensitive C-reactive protein after 12 months of treatment in a retinoid-placebo controlled two-by-two randomized breast cancer prevention trial (Decensi...

Cite
Lazzeroni M, Macis D, Decensi A, et al. The effect of transdermal estradiol or oral conjugated oestrogen and fenretinide versus placebo on haemostasis and cardiovascular risk biomarkers in a randomized breast cancer chemoprevention trial. Ecancermedicalscience. 2008;2:67doi: 10.3332/ecancer.2008.67.
Lazzeroni, M., Macis, D., Decensi, A., Gandini, S., Sandri, M. T., Serrano, D., Guerrieri-Gonzaga, A., Johansson, H., Mora, S., Daldoss, C., Omodei, U., & Bonanni, B. (2008). The effect of transdermal estradiol or oral conjugated oestrogen and fenretinide versus placebo on haemostasis and cardiovascular risk biomarkers in a randomized breast cancer chemoprevention trial. Ecancermedicalscience, 267. https://doi.org/10.3332/ecancer.2008.67
Lazzeroni, M, et al. "The effect of transdermal estradiol or oral conjugated oestrogen and fenretinide versus placebo on haemostasis and cardiovascular risk biomarkers in a randomized breast cancer chemoprevention trial." Ecancermedicalscience vol. 2 (2008): 67. doi: https://doi.org/10.3332/ecancer.2008.67
Lazzeroni M, Macis D, Decensi A, Gandini S, Sandri MT, Serrano D, Guerrieri-Gonzaga A, Johansson H, Mora S, Daldoss C, Omodei U, Bonanni B. The effect of transdermal estradiol or oral conjugated oestrogen and fenretinide versus placebo on haemostasis and cardiovascular risk biomarkers in a randomized breast cancer chemoprevention trial. Ecancermedicalscience. 2008;2:67. doi: 10.3332/ecancer.2008.67. Epub 2008 Feb 06. PMID: 22275964; PMCID: PMC3234057.
Copy Download .nbib Format: NLM
Microsatellite instability evaluation: which test to use for endometrial cancer?.

Journal of clinical pathology

Rafaniello-Raviele P, Betella I, Rappa A, Vacirca D, Tolva G, Guerrieri-Gonzaga A, Bertario L, Barberis M, Bonanni B, Marabelli M.
PMID: 34312297
J Clin Pathol. 2021 Jul 26; doi: 10.1136/jclinpath-2021-207723. Epub 2021 Jul 26.

AIMS: Analysis of microsatellite instability (MSI) is strongly recommended in endometrial cancer (EC) and colorectal cancer to screen for Lynch syndrome, to predict prognosis and to determine optimal treatment and follow-up. In a large monoinstitutional series of ECs, we...

Cite
Rafaniello-Raviele P, Betella I, Rappa A, et al. Microsatellite instability evaluation: which test to use for endometrial cancer?. J Clin Pathol. 2021;doi: 10.1136/jclinpath-2021-207723.
Rafaniello-Raviele, P., Betella, I., Rappa, A., Vacirca, D., Tolva, G., Guerrieri-Gonzaga, A., Bertario, L., Barberis, M., Bonanni, B., & Marabelli, M. (2021). Microsatellite instability evaluation: which test to use for endometrial cancer?. Journal of clinical pathology, . https://doi.org/10.1136/jclinpath-2021-207723
Rafaniello-Raviele, Paola, et al. "Microsatellite instability evaluation: which test to use for endometrial cancer?." Journal of clinical pathology vol. (2021). doi: https://doi.org/10.1136/jclinpath-2021-207723
Rafaniello-Raviele P, Betella I, Rappa A, Vacirca D, Tolva G, Guerrieri-Gonzaga A, Bertario L, Barberis M, Bonanni B, Marabelli M. Microsatellite instability evaluation: which test to use for endometrial cancer?. J Clin Pathol. 2021 Jul 26; doi: 10.1136/jclinpath-2021-207723. Epub 2021 Jul 26. PMID: 34312297.
Copy Download .nbib Format: NLM
Effect Modifiers of Low-Dose Tamoxifen in a Randomized Trial in Breast Noninvasive Disease.

Clinical cancer research : an official journal of the American Association for Cancer Research

DeCensi A, Puntoni M, Johansson H, Guerrieri-Gonzaga A, Caviglia S, Avino F, Cortesi L, Ponti A, Pacquola MG, Falcini F, Gulisano M, Digennaro M, Cariello A, Cagossi K, Pinotti G, Lazzeroni M, Serrano D, Briata IM, Buttiron Webber T, Boni L, Bonanni B.
PMID: 33608319
Clin Cancer Res. 2021 Jul 01;27(13):3576-3583. doi: 10.1158/1078-0432.CCR-20-4213. Epub 2021 Feb 19.

PURPOSE: Low-dose tamoxifen halved recurrence after surgery in a phase III trial in breast noninvasive disease without increasing adverse events. We explored the effect of low-dose tamoxifen in clinically relevant subgroups, including menopausal status, estradiol levels, smoking, body mass...

Cite
DeCensi A, Puntoni M, Johansson H, et al. Effect Modifiers of Low-Dose Tamoxifen in a Randomized Trial in Breast Noninvasive Disease. Clin Cancer Res. 2021;27(13):3576-3583doi: 10.1158/1078-0432.CCR-20-4213.
DeCensi, A., Puntoni, M., Johansson, H., Guerrieri-Gonzaga, A., Caviglia, S., Avino, F., Cortesi, L., Ponti, A., Pacquola, M. G., Falcini, F., Gulisano, M., Digennaro, M., Cariello, A., Cagossi, K., Pinotti, G., Lazzeroni, M., Serrano, D., Briata, I. M., Buttiron Webber, T., Boni, L., & Bonanni, B. (2021). Effect Modifiers of Low-Dose Tamoxifen in a Randomized Trial in Breast Noninvasive Disease. Clinical cancer research : an official journal of the American Association for Cancer Research, 27(13), 3576-3583. https://doi.org/10.1158/1078-0432.CCR-20-4213
DeCensi, Andrea, et al. "Effect Modifiers of Low-Dose Tamoxifen in a Randomized Trial in Breast Noninvasive Disease." Clinical cancer research : an official journal of the American Association for Cancer Research vol. 27,13 (2021): 3576-3583. doi: https://doi.org/10.1158/1078-0432.CCR-20-4213
DeCensi A, Puntoni M, Johansson H, Guerrieri-Gonzaga A, Caviglia S, Avino F, Cortesi L, Ponti A, Pacquola MG, Falcini F, Gulisano M, Digennaro M, Cariello A, Cagossi K, Pinotti G, Lazzeroni M, Serrano D, Briata IM, Buttiron Webber T, Boni L, Bonanni B. Effect Modifiers of Low-Dose Tamoxifen in a Randomized Trial in Breast Noninvasive Disease. Clin Cancer Res. 2021 Jul 01;27(13):3576-3583. doi: 10.1158/1078-0432.CCR-20-4213. Epub 2021 Feb 19. PMID: 33608319.
Copy Download .nbib Format: NLM
Showing 1 to 10 of 10 entries